Dorte Renneberg

USPTO Granted Patents = 16 (Patent Applications = 4)

CIPO Patents = 12 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 16)

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Basel, CH (2011 - 2016)
Allschwil, CH (2012 - 2023)

Company Filing History:

13 out of 217

Actelion Pharmaceuticals Ltd

patents

3 out of 77

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2011-2023

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11739070 - C5A receptor modulators (2023-08-29),

2. 11608341 - Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators (2023-03-21),

3. 9718774 - Indole carboxamide derivatives as P2X7 receptor antagonist (2017-08-01),

4. 9556117 - [object Object] (2017-01-31),

5. 9409917 - Heterocyclic amide derivatives as P2X7 receptor antagonists (2016-08-09),

6. 9388198 - [object Object] (2016-07-12),

7. 9388197 - Heterocyclic amide derivatives as P2X7 receptor antagonists (2016-07-12),

8. 9221832 - Heterocyclic amide derivatives as P2X7 receptor antagonists (2015-12-29),

9. 8664203 - Thiazole derivatives and their use as P2Y12 receptor antagonists (2014-03-04),

10. 8518912 - [object Object] (2013-08-27),

11. 8492555 - Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester (2013-07-23),

12. 8436205 - Tetrahydronaphthalene compounds (2013-05-07),

13. 8314253 - Bridged tetrahydronaphthalene derivatives (2012-11-20),

14. 8288385 - 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines (2012-10-16),

15. 8202885 - Bridged six-membered ring compounds (2012-06-19),

Title: The Innovations and Contributions of Inventor Dorte Renneberg

Introduction: Dorte Renneberg, a distinguished inventor based in Allschwil, Switzerland, has made significant contributions to the field of pharmaceuticals through her innovative research and development efforts. With a portfolio of 16 patents, Renneberg demonstrates a strong commitment to advancing medical science and improving therapeutic options for patients.

Latest Patents: Among her latest breakthroughs are the patents related to C5A receptor modulators. These inventions pertain to derivatives of a specific formula that outline their preparation, pharmaceutically acceptable salts, and their use as pharmaceuticals. The innovations encompass various substituted tetrahydropyrazolo derivatives designed to act as effective C5A receptor modulators. These patents highlight the potential of her compounds in shaping future treatments and pharmaceutical compositions.

Career Highlights: Dorte Renneberg has held prominent positions at leading pharmaceutical companies, including Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. Her work has not only led to numerous patents but has also placed her at the forefront of innovative drug discovery and development processes. Renneberg's contributions have significantly influenced how novel treatments are created and brought to market.

Collaborations: Throughout her career, Renneberg has collaborated with notable colleagues such as Francis Hubler and Kurt Hilpert. These partnerships have fostered an environment of shared knowledge and innovation, driving advancements in drug development and enhancing the overall impact of her work within the pharmaceutical industry.

Conclusion: Dorte Renneberg's work as an inventor serves as an inspiration in the realm of pharmaceutical innovations. With her 16 patents and a commitment to improving healthcare solutions, Renneberg continues to make a lasting impact on the industry. Her contributions, particularly in the development of C5A receptor modulators, not only highlight her expertise but also lay the groundwork for future advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.